Multiple Myeloma Clinical Trial
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
Summary
The purpose of this observational study is to assess HRQoL in relapsed and/or refractory multiple myeloma (RRMM) participants who have previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Eligibility Criteria
Inclusion Criteria:
Must have sufficient command of the Japanese language to understand the study instructions and requirements
Must be a resident of Japan
Must have received prior treatment with:
a proteasome inhibitor,
an immunomodulatory agent, and
an anti-CD38 antibody Subjects must be either 2-4 months, 5-7 months, or 8-11 months post triple class therapy exposure at time of consent
Subject must be diagnosed with multiple myeloma
Exclusion Criteria:
Participants enrolled in a clinical trial that includes at least one novel/ experimental agent at the point of questionnaire completion
Other protocol-defined inclusion/exclusion criteria apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Morrisville North Carolina, 27560, United States
How clear is this clinincal trial information?
